Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium to Develop Mutant Animals for Oxagen

NEW YORK, June 5 - Ingenium Pharmaceuticals has signed an agreement with UKbiotech company Oxagen, to create animal models with defined gene alterations for research into metabolic diseases, the companies said.


The companies did not disclose the financial terms of the agreement.


The project will use Ingenium's genotyping platform to create mammalian models that carry alterations in target genes. Oxagen has identified genes relating to metabolic diseases using its target identification technology.

Ingenium is based in Munich.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.